Pneumococcal vaccine - GlaxoSmithKline

Drug Profile

Pneumococcal vaccine - GlaxoSmithKline

Alternative Names: 2830929A; 2830930A; GSK2830929A; GSK2830930A

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pneumococcal infections

Most Recent Events

  • 17 Mar 2016 Phase-II development is ongoing in European Union
  • 01 Jan 2014 GlaxoSmithKline completes a phase II trial in Pneumococcal infections (in infants, prevention) in Belgium, Czech Republic, Germany, Poland, Spain (NCT01616459)
  • 02 May 2012 Phase-II clinical trials in Pneumococcal infections (in infants, prevention) in Belgium, Czech Republic, Germany, Poland and Spain (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top